32
Participants
Start Date
March 9, 2017
Primary Completion Date
October 8, 2020
Study Completion Date
April 1, 2021
brigatinib
Single arm phase 2 trial to investigate the clinical activity in patients with advanced non-small cell lung cancer
Duke University, Durham
Vanderbilt Unversity Medical Center, Nashville
University of Texas, Southwestern, Dallas
University Of Colorado, Denver
Lead Sponsor
Collaborators (2)
University of Colorado, Denver
OTHER
Duke University
OTHER
Takeda
INDUSTRY
Vanderbilt University
OTHER
University of Texas Southwestern Medical Center
OTHER
University of Pittsburgh
OTHER
Ohio State University
OTHER
Georgetown University
OTHER
Academic Thoracic Oncology Medical Investigators Consortium
INDUSTRY
Criterium, Inc.
INDUSTRY